Pharmacogenomics and Cardiovascular Events | Pharmacogenomics and Effective Treatment With Clopidogrel
Pharmacogenomics and Cardiovascular Events research study
What is the primary objective of this study?
The aim of this biospecimen repository is to evaluate an individual's genotype, identify the
variances, and understand how they relate to treatment with clopidogrel.
Who is eligible to participate?
- Currently taking or prescribed Clopidogrel or under consideration
- Acute/interventionPatients of the Avera Heart Hospital
- Cardiology clinic patients with the Avera Heart Hospital and North Central Heart
- Unable to provide informed consent
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
Pharmacogenomics and Cardiovascular Events
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Genetic:PharmacogenomicsUtilizing pharmacogenomics to determine the most effective treatment
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
ClopidogrelPatients taking or prescribed clopidogrel or under consideration Utilizing pharmacogenomics to determine the most effective treatment
Start Date: June 2012
Completed Date: January 2015
Study sponsors, principal investigator, and references
Principal Investigator: Gareth Davies, PhD
Collaborator: Avera Heart Hospital of South Dakota